Dexamethasone Versus Prednisolone in Acute Exacerbation of Childhood Asthma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

224 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-03

Study Completion Date

2025-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Because of insufficient local comparative data, this study was designed to determine the outcome of intravenous dexamethasone in contrast to oral prednisolone in acute exacerbation of asthmatic children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single Dose Oral Dexamethasone Versus Multi-dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in Children

NCT03698630

Asthma Acute Asthma

COMPLETED PHASE4

Steroids In The Management Of Acute Asthma Exacerbations In Children, Which Form Is More Suitable?

NCT03204760

Steroids In Management Of Acute Asthma Exacerbations

UNKNOWN PHASE2

Comparison of Oral Dexamethasone Doses in Asthma Exacerbation

NCT00942201

Asthma Reactive Airway Disease

COMPLETED NA

Steroids in Children Hospitalized With Asthma

NCT02780479

Asthma Status Asthmaticus Wheezes

TERMINATED PHASE4

Dexamethasone Tolerability in the Treatment of Acute Asthma in Children

NCT00973687

Asthma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The findings of this study would furnish the local data. The results would also provide recommendations to use more appropriate steroid options in the local settings, resulting in aid to improve the quality of life of asthmatic children and their quicker return to daily routine activities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Exacerbation of Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravenous Dexamethasone Group

Patients received a single IV dose of dexamethasone at a dose of 0.6 mg/kg.

Group Type EXPERIMENTAL

Dexamethasone

Intervention Type DRUG

Patients received single IV dose of Dexamethasone at a dose of 0.6 mg/kg

Oral Prednisone Group

Patients were given oral prednisone at a dose of 2 mg/kg/day (max 60 mg) as a single dose for 3 days.

Group Type EXPERIMENTAL

Prednisolone

Intervention Type DRUG

Patients received oral prednisone at a dose of 2 mg/kg/day (max 60 mg) as a single dose for 3 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexamethasone

Patients received single IV dose of Dexamethasone at a dose of 0.6 mg/kg

Intervention Type DRUG

Prednisolone

Patients received oral prednisone at a dose of 2 mg/kg/day (max 60 mg) as a single dose for 3 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children of any gender
* Aged 2-12 years
* Presenting with acute exacerbation of asthma within 24-hours

Exclusion Criteria

* Children with PRAM score of ≥ 10
* Used oral or parenteral corticosteroids in last 4-weeks
* With any chronic condition of lungs (TB, cystic fibrosis), liver (chronic liver disease), kidneys (chronic kidney disease, nephrotic syndrome) or blood (thalassemia, malignancy)

Minimum Eligible Age

2 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No